A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

NCT01609010 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

313

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: rituximab
DRUG: interferon-a-2a

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]